The Latest Cardiac and Vascular News
New PERSIST-AVR study results and SURE-AVR registry data analysis underscore utility of Perceval as a minimally invasive surgical approach for patients with aortic valve stenosis LONDON–(BUSINESS WIRE)–LivaNova PLC (NASDAQ:LIVN) a market-leading medical technology and innovation company, today announced new data from the Perceval® Sutureless Implant Versus Standard-Aortic Valve Replacement (PERSIST-AVR) clinical study and the Sorin Universal Registry on Aortic […]
LONDON–(BUSINESS WIRE)–LivaNova PLC (NASDAQ:LIVN) a market-leading medical technology and innovation company, today announced it will present a poster at the European Society of Cardiology (ESC) Congress 2020 on the potential for autonomic regulation therapy (ART) via vagus nerve stimulation to improve long-term cardiovascular function in patients with heart failure. The virtual Congress runs from Saturday, Aug. 29 […]
LONDON–(BUSINESS WIRE)–LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today reported results for the quarter ended June 30, 2020. For the second quarter of 2020, worldwide sales from continuing operations were $182.2 million, a decrease of 34.3 percent on a reported basis and a decline of 33.1 percent on a constant-currency1 basis, as compared […]
Next generation sutureless surgical technology is based on a clinically proven platform and has been designed to provide valve durability LONDON – ( BUSINESS WIRE ) – LivaNova PLC (NASDAQ: LIVN), a leading medical technology and innovation company, announced today that the Perceval ® Plus Advanced Suture-Free Surgical Aortic Valve is now available for a commercial launch in Europe, having successfully […]
PERSIST-AVR study results presented at American Association for Thoracic Surgery Annual Meeting LONDON–(BUSINESS WIRE)–LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, presented the first data from the Perceval® Sutureless Implant Versus Standard-Aortic Valve Replacement (PERSIST-AVR) clinical study at the 100th Annual Meeting of the American Association of Thoracic Surgery (AATS). The study demonstrated that the Company’s sutureless surgical aortic valve, […]
LONDON–(BUSINESS WIRE)–LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today reported results for the quarter ended March 31, 2020. For the first quarter of 2020, worldwide sales from continuing operations were $242.4 million, a decrease of 3.4 percent on a reported basis and a decline of 1.8 percent on a constant-currency1 basis, as compared […]
Bi-Flow is first bidirectional femoral arterial cannula validated for 29 days’ use LONDON–(BUSINESS WIRE)–LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced its Bi-Flow Extracorporeal Membrane Oxygenation (ECMO) cannula earned CE Mark approval for ECMO procedures where femoral artery cannulation can be applied. Bi-Flow previously received CE Mark in 2019 for cardiac […]
Various products can now be used to treat patients experiencing acute respiratory or cardiopulmonary failure LONDON–(BUSINESS WIRE)–LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced that several of its cardiopulmonary products are now permitted to be used in the U.S. for Extracorporeal Membrane Oxygenation (ECMO) therapy greater than six hours per guidance […]
LONDON–(BUSINESS WIRE)–LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced two abstracts focused on implantable neuromodulation technology for patients with heart failure will be shared at this year’s American College of Cardiology and World Congress of Cardiology Virtual meeting (ACC.20/WCC). In lieu of traditional in-person presentations, ACC.20/WCC will share all abstracts and posters […]
LONDON–(BUSINESS WIRE)–Feb. 25, 2020– LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced it received U.S. Food and Drug Administration (FDA) 510(k) clearance for a device modification to its 3T Heater-Cooler® devices. The modification includes the installation of a 3T Aerosol Collection Set, as well as testing that demonstrates the effectiveness of its operating instructions. This modification […]
